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Chronic urticaria is a common condition characterized by recurrent hives lasting several weeks ormonths and is usually idiopathic.
Approximately half of the individuals with chronic urticaria will present with episodes of angioedema that can be severe and
debilitating. In this report, we describe a 47-year-old Hispanic male who presented initially for an evaluation of chronic hives
following hospitalization due to hive-induced anaphylaxis. The individual had a history significant for urticaria and angioedema
beginning in his early 30s. Interestingly, both the individual’s 41-year-old sister and 12-year-old daughter were also affected with
chronic urticaria and severe angioedema. Whole exome sequencing of the proband and several family members revealed a
heterozygous variant of uncertain significance in exon 2 of TNFAIP3, denoted as c.65G>A (p.R22Q), in all affected members.
Variants in TNFAIP3 have been associated with multiple autoimmune diseases, susceptibility to allergy and asthma, and periodic
fever syndromes, suggesting that this variant could potentially play a role in disease.
1. Introduction
Chronic urticaria is a common skin disorder characterized
by recurrent hives lasting more than six weeks or hives that
recur over several months or years [1, 2]. It is mainly a disease
of adults with women being more affected than men [3].
Chronic urticaria is usually idiopathic, arising spontaneously
without a stimulus. Other common types include physical
urticarias that are caused by physical stimuli such as cold,
heat, or pressure. Various types of urticaria may coexist to-
gether, which is not uncommon [3]. Angioedema is a swelling
of the deeper epidermal and dermal layers of the skin. The
association between chronic urticaria and angioedema is well
established [4, 5]. Genetic factors may play a role in chronic
idiopathic urticaria, but the mechanism of disease is largely
unknown [6]. In this report, we describe a patient with a
several-year history of chronic hives, angioedema, skin flush-
ing, and swelling. Whole exome sequencing (WES) did not
detect any causative variants in known disease genes but
did identify a variant in tumor necrosis factor-alpha-induced
protein 3 (TNFAIP3, known commonly as A20) that is possi-
bly associated with the reported phenotype.
2. Case History
A 47-year-old Hispanic male was initially referred to the
Mayo Clinic at 34 years of age due to severe episodes of
angioedema (occurring every three to four months) and
history of chronic urticaria. The initial onset of urticaria
occurred in 2002 while the proband was living in Italy. He
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has since relocated to the United States, where he sought
treatment for his urticaria flares. The proband reported that
episodes of urticaria occur when his skin is exposed to hot or
cold temperatures or significant pressure.
The proband tried numerous treatment modalities to
suppress his urticaria, including the following antihistamines:
levocetirizine, cetirizine, fexofenadine, and loratadine. Pred-
nisone and steroid injections were the only treatments that
cleared the patient’s hives; however, treatment with predni-
sone was eventually stopped due to side effects. His elevated
levels of IgE suggested that the hives were autoimmune in
nature, though the accompanying tryptase elevation led to the
consideration ofmastocytosis.The patient had a normal bone
marrow biopsy (differential and aspirate), a complete blood
count (CBC) with differential within normal limits, and a
normal mast cell panel (CD2, CD25, CD69, and CD117). His
anti-IgE receptor antibody was elevated at 18.5% (reference
range: <13%) and his C1q complement was elevated at 43
(12–22mg/dL). He also had a normal TSH of 2.0 (>20 years:
0.3–4.2mIU/L) and serum protein electrophoresis that was
within normal limits. His tryptase levels were consistently
elevated and ranged from 13.9 and 19.2 (<11.5 ng/mL), indi-
catingmast cell activation. Due to the absence of mast cells in
the bone marrow biopsy, the patient did not meet diagnostic
criteria for mastocytosis and was ultimately diagnosed with
chronic urticaria. At 37 years of age, the patient began expe-
riencing “attacks” approximately every two weeks, which he
described as involving hives, fever, weakness, diaphoresis,
and diarrhea. The patient also experienced episodes of dizzi-
ness when standing after walking only a few feet.
Upon ascertainment of family history, we found that one
of the proband’s sisters and his daughter both shared his
symptoms of hives and angioedema (Figure 1).The proband’s
daughter, who was 12 years of age at the time of evaluation,
had episodes of hives and swelling of her hands and feet. She
participated in gymnastics but had to discontinue this activity
due to swelling of her feet after practice. She has also devel-
oped hand swelling after playing the cello.
3. Methods
3.1. Whole Exome Sequencing. Using genomic DNA extract-
ed from the proband, his mother, sister, and daughter, the
Agilent Clinical Research Exome kit was used to target exonic
regions and flanking splice junctions of the genome. These
regions were sequenced by massively parallel sequencing
on an Illumina HiSeq with 100 bp paired-end reads (mean
depth of coverage: 119x; quality threshold: 94.9%). Bidirec-
tional sequence was assembled, aligned to reference gene
sequences based on human genome build GRCh37/UCSC
hg19, and analyzed for sequence variants using a custom-
developed analysis tool (Xome Analyzer, GeneDx). Capillary
sequencing was used to confirm the presence or absence of all
potentially pathogenic variants identified in both the proband
and relative samples.
3.2. Structural Modeling. TNFAIP3, also known as A20, is an
ubiquitin-editing enzyme, which has dual roles in ubiquitin
ligase and deubiquitinase activity. The N-terminal domain of
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Figure 1: Family pedigree. Standard pedigree symbols are used.
An arrow indicates the proband. The numbers inside the symbols
represent the number of family members. The numbers at the right
lower side of the symbols represent current age or age at death of
the individuals. Asterisks indicate individuals that underwent whole
exome sequencing.
TNFAIP3 contains an ovarian tumor (OTU) domain, involv-
ed in deubiquitinating Lys-63-polyubiquitin chains in a num-
ber of substrates.TheC-terminal domain of TNFAIP3 is com-
posed of seven zinc finger domains that coordinate ubiquitin
ligase activity, including the addition of lysine-48-linked
ubiquitin chains that are necessary for targeting substrates for
proteasomal degradation [7, 8].
HumanTNFAIP3 sequencewas taken from theNCBIRef-
erence Accession number NG 032761 version NG 032761.1
and was used for computer-assisted modeling. Monte Carlo
simulations were performed on the full-length wild type
protein (791 amino acids) and the p.R22Q variant. The X-
ray refinement for Monte Carlo was built using YASARA
SSP/PSSM method [9–14]. The structure was relaxed to the
YASARA/Amber force field using knowledge-based poten-
tials within YASARA. The side chains and rotamers were
adjusted with knowledge-based potentials, simulated anneal-
ing with explicit solvent, and small equilibration simulations
using YASARA’s refinement protocol [15]. The entire full-
length structure was modeled, filling in any gaps or unre-
solved portions from the X-ray.
Refinement of the finalized models was completed using
either Schrodinger’s LC-MODMonte Carlo-basedmodule or
NAMD2 protocols. These refinements started with YASARA
generated initial refinement [9–11, 13].The superposition and
subsequent refinement of the overlapping regions yielded
a complete model for TNFAIP3. The final structures were
subjected to energy optimization with PR conjugate gradient
with an R-dependent dielectric.
Atom consistency was checked for all 791 amino acids
(13,028 atoms) of the full-length wild type model and 791
amino acids (13,028 atoms) for the p.R22Q variant, verify-
ing correctness of chain name, dihedrals, angles, torsions,
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nonbonds, electrostatics, atom typing, and parameters. Each
modelwas exported to the following formats:Maestro (MAE)
and YASARA (PDB). Model manipulation was done with
Maestro (Macromodel, version 9.8, Schrodinger, LLC, New
York, NY, 2010) or Visual Molecular Dynamics (VMD) [16].
Analyses were restricted to theN-terminus region containing
the first 350 amino acids given the length andC-termdistance
from the site of mutation.
Monte Carlo dynamics searching (LCMOD-MC) was
completed on each model for conformational sampling,
using methods previously described in the literature [17–20].
Briefly, each TNFAIP3 variant system was minimized with
relaxed restraints using either Steepest Descent or Conjugate
Gradient PR and then allowed to undergo theMC search cri-
teria, as shown in the literature [17–20].The primary purpose
of MC, in this scenario, is to examine any conformational
variability that may occur with different mutations in the
region near the mutation and the possible effect on TNFAIP3
structure and function.
4. Results
4.1. Exome Sequencing Results. WES of the proband
uncovered a novel variant in TNFAIP3 (Chr6(GRCh38):
g.137871292G>A; NM 001270507.1: c.65G>A; p.(Arg22Gln)),
which could possibly correlate with the proband’s disease
phenotype.The p.R22Q variant is absent from ExAC (Exome
Aggregation Consortium) and has only been observed in
1/30936 whole genomes sequenced in gnomAD (Genome
Aggregation Database) [21]. Of note, this variant was seen in
1/838 Latino genomeswith a predictedminor allele frequency
(MAF) of 0.001193%, suggesting that it may bemore common
in Latino populations. The Arg22 residue is conserved across
species down to zebrafish (Danio rerio), and in silico
prediction algorithms predict the variant to be deleterious
(PredictSNP2 deleterious score: 1.0000; CADD deleterious
score: 22.6000; FATHMM deleterious score: 0.9806) [22].
This variant results in a semiconservative amino acid substi-
tution that may impact secondary protein structure, and
more detailed studies including in silicomolecular modeling
anddynamics simulationswerepursued. Based on theACMG
2015 guidelines, the c.65G>A (p.R22Q) variant was classified
as a variant of uncertain significance (VUS) [23]. The pro-
band’s mother was found to be negative for the p.R22Q vari-
ant (the proband’s father was deceased), whereas both his
daughter and sister (both affected) were heterozygous for
the VUS. Another pathogenic variant was detected in GJB2
(Chr13(GRCh38): g.20189547del; NM 004004.5: c.35del;
p.Gly12Valfs∗2; exon 2) in the proband and his mother only,
which may be associated with his mild hearing loss.
4.2. Structure-Function Results. When comparing the wild
type and the p.R22Q variant, we found the energetic sta-
bility of the object based on ΔG per amino acid calcula-
tions to be comparable. The wild type object stability was
53.12 kcal/mol∗A˚2, while the p.R22Q variant results in a net
increase in free energy of 0.755 kcal/aa∗mol∗A˚2, which could
be locally destabilizing [17–19, 24–27]. This object stability
was positive, indicating that some dynamic changes are likely
with a molecular simulation for conformational sampling.
Thus, we examined the local residues and determined that an
electrostatic calculation may be useful to explain the change
in function. The molecular models for the full structure and
its variant form were generated (Figure 2) using previously
described methods [17–20, 24, 27–34].
Local residues within a 12 A˚ cutoff near the variant site
(p.R22Q) include Y11, M15, K17, V19, R22, E23, R24, T25,
Y111, Q116, T118, L120, andV121, which forms around a helical
region that has two interacting helices and a loop region start-
ing at Y111 and extending to L120 (Figure 2). The R22 residue
has interesting bridging interactions with the amino acids in
the parallel helix, which includes Y111, T118, and V115. While
the residues from the other helix are interacting with the N-
terminus arginine, there is also some helix-helix interaction
with T25-V121 and Y11-Q116 (Figure 2).
Mapping electrostatics was accomplished using the Pois-
son-Boltzmann calculation for solvation on the entire 791-
amino-acid structure.The effects of the changeswere strongly
pronounced on electrostatic distribution with a +3 KT/E cut-
off for both. The wild type structure (all 791 aa) shows a dis-
tinct distribution of charge around R22, which forms some
definite contours for bindingpartner association and strength-
ens the domain structure. This may be useful for partner
proteins or substrates (Figure 3).The p.R22Q structure is pre-
dominately negative in charge distribution at the immediate
vicinity of position 22 (within 4 A˚) and has a large positive
distribution in a ring-like configuration around that zone
(>4 A˚ but<12 A˚) (Figure 3),which includes residuesY11,Q116,
T118, L121, and K17.This kind of potential charge distribution
is consistent with an electrostatic funnel that directs charge
partners towards selected residues to bind [17–19, 24–27].
The electrostatics calculations from the wild type when
compared with p.R22Q variant show some interesting
changes due to the weakening of the Arg to Gln mutation
among residues D119, T25, E23, V19, and T118, which are
within interaction distance of Q22. Also of note is that distri-
bution of the charge for the “funnel” observed (Figure 3(a)) is
demonstrated to be weaker, with shallower contour surfaces
and introduction of a large charge “hole” found on the far
right hand side to the right of Val121 and Pro26.The positively
charged ring is dissipated in theGln22 structure, whichwould
indicate that the effect noted above may be eliminated,
potentially contributing to the altered TNFAIP3 function.
5. Conclusion
This report describes a 47-year-old Hispanic male with an
extensive history of chronic urticaria and angioedema that
various treatment modalities failed to resolve. It was ini-
tially suggested that the patient might have mastocytosis or
autoimmune-related hives due to his elevated tryptase and
IgE levels, respectively. Bone marrow biopsy and computer-
ized tomography (CT) scans ruled out visceral involvement
by systemicmastocytosis, and the patient was later diagnosed
with chronic urticaria. The cause of his chronic urticaria
is unknown; however, a history of hives in the proband’s
daughter and sister led to genetic testing of some of his family
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Figure 2: TNFAIP3 molecular model for full-length human sequence consisting of 791 amino acids and the variant p.R22Q. (a) Full-length
model for the entire TNFAIP3 structure with electrostatic mapping onto the ribbon structure is shown.The density map is cut away to reveal
where Arg22 and Gln22 play a role in the interaction between the helix and the loop. (b) Zoom-in on the wild type for the Arg22 residue from
the full-length model to better show the interacting residues. (c) Zoom-in on the region around the Gln22 variant, showing nearby residues.
All protein residues shown in licorice rendering and using standard element coloring (C-gray, O-red, N-blue, H-white, and S-yellow) except
for the highlighted residues (Arg22: orange carbons, Gln22: green carbons).
(a) (b)
Figure 3: TNFAIP3 electrostatic mapping for interaction potential. Full-length model for the entire TNFAIP3 structure with electrostatics
calculated using Poisson-Boltzmann (PB) calculation overlaid onto the structure.The relevant region is zoomed in to show all residues within
12 A˚ of residue position 22. (a) Interacting residues surrounding Arg22 are given with PB electrostatics mapped onto the protein surface. The
white label gives the residues’ position. The electrostatic map shows the negative to positive (red to blue) distribution and the contours and
shape of the protein in this region. (b) Mutant variant p.R22Q TNFAIP3 model is given with electrostatics overlaid, indicating a muted
negative charge. The depiction is similar to that in (a).
members. Two genes were identified throughWES:TNFAIP3
and GJB2.
The c.35delG variant in GJB2 has been reported previ-
ously in association with autosomal recessive nonsyndromic
hearing losswhen present in the homozygous state orwhen in
transwith another pathogenic variant [35].This variant is the
most commonGJB2 pathogenic variant among individuals of
European ancestry, and the hearing loss present in individuals
homozygous for the c.35delG variant ranges from mild to
profound [36]. Most individuals known to be heterozygous
for this variant have normal hearing, although subclinical
differences in the otoacoustic emissions of carriers have been
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noted upon audiologic examination [37].Theproband’smoth-
er was heterozygous for the c.35delG variant inGJB2while his
sister and daughter did not carry this variant.
The proband, his daughter, and his sister who are all
affected with chronic urticaria and angioedema each carry
the c.65G>A (p.R22Q) variant in TNFAIP3. The variant is
absent in the proband’smotherwho is unaffected.This variant
in TNFAIP3 has not been reported previously as pathogenic
or benign to our knowledge and was classified as a VUS.
However, TNFAIP3 is known to be involved in immune and
inflammatory responses signaled by cytokines, such as tumor
necrosis factor-alpha and interleukin-1 beta [38]. Addition-
ally, multiple variants within the gene have been associated
with autoimmune diseases, susceptibility to allergy and asth-
ma, and periodic fever syndromes [39].
TNFAIP3 is a ubiquitin-editing enzyme that participates
in ubiquitin ligase and deubiquitinase activities. It is also
known to have multiple overlapping functions between nu-
clear factor kappa B (NF𝜅B) and interferon regulatory factors
(IRF) [8, 40]. There is evidence of cross talk between these
two signaling pathways and their roles in the inflammatory
and antiviral responses, which positions TNFAIP3 as a key
effector of the innate immune response [41]. Recently, Zhou
et al. (2016) identified individuals from six different fami-
lies affected with a Behc¸et-like autoinflammatory syndrome
(MIM: 616744) that has a variable presentation including
uveitis, chorioretinal scarring, oral, gastrointestinal, and gen-
ital ulcers, gastrointestinal inflammation, polyarthritis, rash,
periodic fevers, and autoinflammation with the production
of autoantibodies and increased circulating proinflammatory
cytokines [42]. The age of onset for this disorder is usually
in the first or second decade; however, only a few cases have
been reported to date.
Currently, there is no known association between mis-
sense variants inTNFAIP3 and familial chronic urticaria with
angioedema. Many patients with chronic urticaria improve
with anti-IgE therapy (omalizumab), suggesting that inap-
propriate activation of mast cells and basophils may play a
role in disease pathogenesis. It has also been proposed that
some individuals with chronic urticaria may produce IgE
directed against self-antigens, but evidence for this has been
lacking. The proband in this study had elevated tryptase and
IgE levels, suggesting that he may benefit from a trial of this
therapy in the future. Interestingly, TNFAIP3 has been shown
to regulate inflammation downstream of themast cell antigen
receptor module as well as the alarmin receptor, IL-33R [43].
Heger et al. (2014) showed that mast cell-specific ablation
of Tnfaip3 in mice exacerbated disease in mouse models for
rheumatoid arthritis and asthma, suggesting that dysregula-
tion of mast cell inflammatory responses via Tnfaip3 loss can
contribute to disease pathology [43].
In summary, we report a novel variant in TNFAIP3 in
three family members, which potentially correlates with a
phenotype of chronic urticaria. Additional studies, including
functional analyses, will be necessary to determine the role of
TNFAIP3 variation in susceptibility to chronic urticaria.
Additional Points
Limitations.Although there were no other disease-associated
variants identified by WES, it is possible that this individual
may harbor additional sequence variant(s) that are unde-
tectable by this test. Chronic urticaria is also a relatively com-
mon disorder and may have a nongenetic etiology. However,
cases with a strong family historymay beworthy of additional
study in order to identify underlying geneticmechanisms that
may be dysregulated in this condition.
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